What Dorevitch Pathology does

Dorevitch Pathology is a Victoria-based regional provider of diagnostic pathology services, operating as a trading name of Healius Pathology Pty Ltd within the Healius Limited group (a top-100 ASX-listed entity). The company runs 400-500+ collection centres across Victoria with mobile collection services for homebound and residential-care patients, backed by NATA-, ISO 15189-, ISO 17025-, AS4308-, AS4760-, and TGA-accredited laboratories. Its service portfolio spans routine blood, body-fluid, tissue, cytology, infectious-disease, and genetic testing for patients referred by GPs and specialists; commercial drug-and-alcohol, employee-wellness, and biological-monitoring testing for employers; and laboratory services supporting Phase I-IV clinical trials for pharmaceutical and biotech sponsors. Technology infrastructure is built around the Medway platform suite — Medway Results for real-time clinician access to pathology results, Medway Practice for consumable ordering and courier requests, eReferrals for digital referral sharing, Telehealth integration, and the Medway Clinical Trials Portal with HL7-based electronic ordering and protocol-specific exclusion flagging. Electronic Data Interchange (EDI) integrates results into clinician clinical systems.\n\nThe business model is a multi-stream revenue mix. The largest stream is Medicare bulk billing for tests covered under the Medicare Benefits Schedule, supplemented by out-of-pocket payments from patients for non-covered specialized, insurance, employment, and immigration testing. Commercial revenue comes from employer drug-and-alcohol screening (instant devices, laboratory screening, and LCMS confirmation), occupational-health and biological-monitoring programs sold through a dedicated commercial team, and clinical-trial lab services with full logistics and data management. Distribution is overwhelmingly physical — collection centres, mobile collections, and on-site employer services — augmented by online appointment booking and digital clinician platforms. Go-to-market is referral-driven: GPs, specialists, and hospitals direct patients to collection centres, while a separate enterprise sales motion covers employer and pharma clients. Customers span four segments (patients, healthcare providers, commercial/employer clients, and research/clinical-trial organizations), with AI referenced as a pathologist-assistive tool under human oversight rather than as an automated diagnostic system.

Name

Dorevitch Pathology

Legal name

Healius Pathology Pty Ltd

Website

https://dorevitch.com.au

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Dorevitch Pathology is a Victoria-based diagnostic pathology provider operating 400+ collection centres and accredited laboratories, serving patients via GP referrals, employers via workplace drug and wellness testing, and pharmaceutical sponsors via clinical trial lab services under the Healius network.

Ownership category

akta.pro rank

Product category

Diagnostic Pathology Services

NAICS

Medical Laboratories (621511), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)

akta.pro secondary industries

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Pathology diagnostics
• Medical laboratory testing
• Diagnostic pathology services
• Clinical trial laboratory
• Workplace drug testing

Headquarters

HQ city

Heidelberg

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Medicare/Bulk Billing Services: Bulk billing for all pathology tests covered under the Medicare Benefits Schedule (MBS). Revenue received from Medicare Australia for bulk-billed services.
2. Out-of-Pocket Patient Payments: Patients pay out-of-pocket for tests not covered by Medicare, including specialized tests, insurance/employment testing, immigration services, and non-Medicare services.
3. Commercial Drug & Alcohol Testing: Drug and alcohol testing services for employers including instant devices, laboratory screening, and LCMS confirmation testing under AS4308 and AS4760 standards.
4. Employee Wellness & Occupational Health: Occupational health screening services for employers including pre-employment health checks, wellness screening, and biological monitoring testing.
5. Clinical Trial Services: Comprehensive lab services for pharmaceutical, biotech, and research organizations supporting clinical trials (Phases I-IV), including testing, logistics, and data management.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

Dorevitch Pathology is a Victoria-based diagnostic pathology services provider operating 500+ collection centres and accredited laboratories. It delivers routine and specialised pathology testing (anatomical pathology, chemical pathology, haematology, immunology, microbiology, genetics) to patients referred by clinicians, supports clinicians through the Medway digital platform, and provides commercial services including workplace drug and alcohol testing, occupational health screening, biological monitoring, and clinical trial laboratory services for pharmaceutical and biotech clients.

Product overview

Dorevitch Pathology provides a comprehensive pathology diagnostics platform with multiple integrated service layers. Core clinical services include Medway Results (real-time diagnostic reporting), Medway Practice (consumable ordering and courier management), eReferrals (digital referral handling), Telehealth, Test Reference Manual, and CPD-accredited education. Patient-facing offerings include the Warfarin Management Clinic and Mobile Collections for homebound patients. Commercial services encompass Drug & Alcohol Testing (AS4308/AS4760 accredited), Employee Wellness Screening, Biological Monitoring Testing, and Research & Clinical Trials (Phases I-IV). The Medway Clinical Trials Portal supports pharma and biotech clients with end-to-end trial workflow digitization. All services operate under the Healius Pathology national network, which is part of a top 100 ASX publicly listed entity.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug & Alcohol Testing Accredited workplace drug and alcohol testing services including urine, oral fluid, hair testing, and breath analysis, delivered under AS4308 and AS4760 standards for employers in Victoria and South Australia.
• Employee Wellness Screening Tailored employee wellness programs including occupational risk testing, pre-employment health checks, and ongoing health monitoring for employer organisations.
• Biological Monitoring Testing Testing services measuring hazardous substances in blood or urine for workplace safety, including baseline monitoring, ongoing health monitoring, and employee health concern assessments.
• Research & Clinical Trials Laboratory Services Comprehensive laboratory services for clinical trials (Phases I-IV) supporting pharmaceutical, biotech, and research organisations with testing across 2,000+ tests, specimen logistics, and data management.
• Medway Clinical Trials Portal Digital portal for clinical trial management offering secure real-time result delivery, HL7 electronic ordering, protocol-specific exclusion flagging, blinding solutions, and simplified invoicing for pharmaceutical and biotech research clients.
• Medway Results Real-time diagnostic results platform enabling clinicians to access patient pathology results anywhere, anytime.
• Medway Practice Practice management portal allowing clinicians to order consumables and request courier services in one place.
• Warfarin Management Clinic Blood monitoring service for patients to manage warfarin dosage safely under clinician oversight.
• Mobile Collections Home or facility specimen collection service for patients unable to attend collection centres due to medical, mobility, or residential care needs, prioritised based on clinical need.

Quantifiable outcome

• Routine pathology tests generally processed and sent to doctors within 48 hours of collection
• +1 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• MedwaycoreTechnology or IntegrationDigital platform partnership providing real-time pathology results access for clinicians (Medway Results) and practice management tools including consumable ordering and courier requests (Medway Practice). Also includes Medway Clinical Trials Portal for research clients.
• Agilex BiolabssupportingTechnology or IntegrationSpecialized bioanalytical testing partnership for clinical trials, with FDA-inspected facilities providing advanced analytical capabilities for pharmaceutical research.
• Healius Pathology NetworkcoreStrategic or Co-development PartnerPart of the Healius Pathology national network comprising premier medical laboratories throughout Australia including Laverty Pathology, QML Pathology, Abbott Pathology, Western Diagnostic Pathology, TML Pathology, and others. Provides governance, support infrastructure, and national logistics network.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sonic Healthcare Limited: Sonic Healthcare is the largest pathology provider in Australia and the dominant competitor to Dorevitch. It operates multiple regional pathology brands including Melbourne Pathology (Victoria), Sullivan Nicolaides (QLD), and Capital Pathology (ACT), and competes directly for clinician referrals, employer testing contracts, and clinical trial mandates with a similar end-to-end service offering.
• Australian Clinical Labs Limited: Australian Clinical Labs is an ASX-listed pathology operator providing diagnostic testing services across multiple Australian states. It competes head-to-head with Dorevitch in clinician referral-based diagnostic pathology and operates a comparable network of collection centres with bulk-billing Medicare economics.
• Melbourne Pathology: Melbourne Pathology is a Victorian-focused pathology provider (Sonic Healthcare subsidiary) that competes directly with Dorevitch for GP and specialist referrals across metropolitan Melbourne and regional Victoria. It offers an overlapping test menu, Medicare bulk billing, and employer services.
• Sullivan Nicolaides Pathology: Sullivan Nicolaides Pathology is a major Sonic Healthcare subsidiary providing diagnostic pathology services, with strengths in esoteric and specialist testing. It is directly comparable to Dorevitch in offering comprehensive test menus, clinical trial lab services, and clinician-focused digital result delivery.
• Capital Pathology: Capital Pathology is a Sonic Healthcare subsidiary providing community-based pathology services in the ACT and surrounding NSW region. It competes with Dorevitch for clinical trial contracts and employer occupational testing, with comparable NATA-accredited laboratory capabilities and bulk-billing economics.
• Healthscope Pathology: Healthscope Pathology is a national pathology provider (formerly under Healthscope, now under Healthe Care ownership) offering diagnostic testing services. It competes with Dorevitch for clinician referrals and clinical trial work, with similar bulk-billed test offerings and a multi-state collection centre network.

Emerging players

• 4D Path: 4D Path is an emerging AI-driven digital pathology company focused on computational diagnostics. While not a direct collection-centre competitor, it represents a future-facing technological adjacency to Dorevitch's AI-augmented diagnostic capabilities and signals where pathology interpretation could be disrupted.

Regional players

• Laverty Pathology: Laverty Pathology is a sister brand within the Healius Pathology network serving NSW and ACT. It operates with the same parent infrastructure, NATA accreditations, and Medway digital platform as Dorevitch but in a different geography, making it a structural sibling rather than direct competitor but directly comparable on operating model.
• QML Pathology: QML Pathology is a Healius Pathology sister brand serving Queensland with the same corporate infrastructure, accreditation profile, and digital platform as Dorevitch. Geographic separation makes it a sibling rather than direct competitor, but it is directly comparable in scale, test menu, and commercial service offering.

Others

• Healius Limited: Healius Limited is the ASX-listed parent company of Dorevitch Pathology and the broader Healius Pathology network. It is the ultimate holding entity providing governance, capital allocation, and shared services, and is the entity through which Dorevitch's strategic and financial direction is set.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dorevitch Pathology